Reviews
G enomic discoveries provide the basis for the evolution of offering care tailored to the genetic makeup of the individual-an approach that has come to be known as personalized medicine. Pharmacogenomics (PGx) has been defined as "the study of how an individual's genetic inheritance affects the body's response to drugs. … Pharmacogenomics combines traditional pharmaceutical sciences such as biochemistry with annotated knowledge of genes, proteins, and single nucleotide polymorphisms." 1 Although the distinctions between PGx and pharmacogenetics are minimal, PGx generally refers to the study of the interactions among multiple genes/gene products and drug response, whereas pharmacogenetics is often used to describe the effects of a single gene. The National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH) is working with a wide range of health professions to improve genomics education in order to prepare them to use emerging genomic discoveries appropriately. From November 30 through December 1, 2011, stakeholders in pharmacy education, including representatives of physician, nursing, and physician assistant communities, met at NHGRI to discuss pharmacist education. In particular, the meeting explored the current status and perceived needs of pharmacist training relevant to PGx competency.
Participants (Table 1 ) discussed the unique position of pharmacists as health professionals providing care to patients in various practice settings (e.g., from the community to tertiary care settings), working independently or collaboratively with other health care providers, strategies for addressing PGx education for the distinct groups in pharmacy (e.g., community pharmacy, health-system pharmacy, managed care pharmacy, clinical and consulting pharmacists), and development and dissemination of educational resources.
The meeting was the fourth in a series of NHGRI meetings on genomics education and was preceded by meetings with nursing, physician assistant, and primary care physician communities. A major impetus for the current meeting was the February 2011 publication of a NHGRI strategic plan for the field of genomics. 2 This report identified health professional education as an important cross-cutting issue for realizing the promise of personalized medicine. The content of the NHGRI report was in turn influenced by previous deliberations undertaken by the now inactive Secretary's Advisory Committee on Genetics, Health, and Society (SACGHS) of the Department of Health & Human Services (HHS). SACGHS produced several reports describing "the growing need among health care professionals for knowledge in this area [genetics and genomics], which is paving the way for more individualized approaches to detect, treat and prevent many diseases." 3 
The pharmacist workforce
The 2010 statistics from the Department of Labor, Bureau of Labor, showed that 274,900 pharmacists were practicing in the United States. Most were employed in community (62%) and hospital (23%) settings. Others work in mail service operations, physicians' offices, outpatient care centers, nursing care facilities, and government positions, as well as work as consultants. Job opportunities are expected to grow by 25% between 2010 and 2020, nearly double the average for all professions, as a result of increasing medical needs of the aging U.S. population and the development of new drug therapies. Patients access pharmacists for explanations about drug selection, dosage, and adverse effects and to understand claims about medication effectiveness. The demand for pharmacists' services is expected to grow as prescribing practices become more complex and the patients' genome is increasingly used to guide treatment options. An important question is how pharmacists, physicians, and other health care providers will partner to interpret genomic data and select the best treatment for their patients.
state of PGx
Genetic variation has long been known to influence how medications affect individuals. A classic example dating to the 1950s is the hemolytic anemia induced by giving primaquine to individuals with glucose-6-phosphate dehydrogenase deficiency. 4 In 2012, there have been many examples of well-characterized genetic variations that predict drug effectiveness, guide dosing, or predict the likelihood of adverse reactions. More than 100 Food and Drug Administration (FDA)-approved drugs mention PGx in required labeling. 5 Several drugs include black box warnings regarding the impact of PGx on safe use. The an-
At a Glance
Synopsis: Discoveries in genomics relevant to medication selection and management are advancing exponentially. A variety of pharmacist organizations and other stakeholder groups attended a 2-day meeting convened by the National Human Genome Research Institute of the National Institutes of Health to discuss the status of pharmacogenomics (PGx) education for pharmacists. Barriers and facilitators to enhanced PGx education and important next steps to ensure preparation of pharmacists were explored.
Analysis ticonvulsant drug carbamazepine is one such example. In the presence of the human leukocyte antigen allele HLA-B*1502, found mainly in people of Asian descent, the drug can cause toxic epidermal necrosis, which is a potentially fatal condition. FDA issued an alert in 2007. Labeling now states the need for genotyping in individuals of Asian ancestry for the allele before starting carbamazepine treatment. 6 Other commonly prescribed drugs that have FDA warnings or precautions highlighting PGx include codeine, clopidogrel, citalopram, and warfarin.
Cancer therapies are increasingly selected according to genomic information derived from tumor and germline DNA. For example, patients with colorectal cancer whose tumors contain KRAS mutations in codon 12 or 13 fail to respond to the antiepidermal growth factor drugs cetuximab and panitumumab. In 2009, FDA updated its labeling for the two compounds, stating that retrospective subset analyses of metastatic or advanced colorectal cancer trials failed to show a treatment benefit in patients whose tumors contained the above KRAS mutations. KRAS genotyping of tumor tissue is now recommended for all patients with metastatic colorectal cancer. 7 As specialists in medication management, pharmacists are well positioned to ensure that pharmacogenomic testing is considered, when appropriate, during patient care. Further, pharmacist practice can be collaborative in nature; in some settings, pharmacists serve as educators for both patients and health care providers regarding medication decisions. Medical home models of care provide opportunities for embedding pharmacists into interprofessional practices to improve drug therapy outcomes and cost effectiveness.
Perspectives on genomics education
The effect that human genetic variation has on drug response is generally taught early in pharmacist training, often as part of early curricular offerings in pharmacy school. The American Association of Colleges of Pharmacy appointed an academic affairs committee a decade ago to guide implementation of PGx in pharmacy schools and colleges nationwide. Topics being addressed include developing practice guidelines and reimbursement policies, dealing with regulatory and privacy issues, creating tools to manage workflow and data, and educating patients and fellow health care practitioners about utilization of genomics information in prescribing. Since then, PGx competency has been incorporated as part of a "science foundation" that faculty, practitioners, and other stakeholders deemed essential to the development of pharmacists and as such is relevant to the accreditation process for pharmacy schools. 8 The number of schools and colleges of pharmacy that include PGx in their PharmD curriculum has more than doubled since 2005. 9 However, available evidence suggests that current paradigms for genomic education may be insufficient to ensure that pharmacists will confidently apply the information in practice. In a recent survey of nearly 500 academic health care system pharmacists, 85% agreed that knowledge of PGx is important and 65% agreed that pharmacists should be able to provide patients with information about the appropriate use of pharmacogenomic testing. However, only 37% felt that they had the knowledge and confidence to do so. 8 Widely and freely available resources for PGx education for pharmacy school faculty and practitioners are scarce. PGx education and data resources for scientists and health practitioners were described for attendees ( 
Goals of the meeting
To build on this PGx foundation and plan for future educational needs, this meeting was organized to accomplish the following goals: (1) define the landscape of pharmacist education in genomics from the perspective of genetics, pharmacist care, pharmacy practice, and academic pharmacist communities; (2) identify core educational needs in genomics, as defined by pharmacists; (3) identify opportunities and barriers facing efforts to enhance pharmacist genomic literacy; (4) propose concrete strategies to take advantage of existing opportunities for genomics education, including interdisciplinary collaborations, at various stages of health professional education; and (5) plan next steps for strategically addressing pharmacist education. Most participants were representatives from pharmacy organizations and federal agencies. Together they discussed plans for addressing PGx competencies, accreditation standards and guidelines, research, policy, ethics, advocacy, patient counseling and education, decision making, practice models, pharmacy management, compensation, e-prescribing practices and technologies, and PGx applications in the various practice settings.
Participants' presentations demonstrated the varied approaches for addressing these topics (Table 3) . Reports from individual organization representatives identified current approaches, including developing traditional or Web-based education programs. Others are looking for collaboration among researchers and educators for advancing knowledge and practice and for optimizing resources. Additional efforts include publishing articles and books about the science and application of PGx; holding workshops, forums, and conferences to discuss business models, ethics, accreditation issues, training, and patient education; studying PGx as it applies to specific diseases and known gene alleles; and looking for health informatics solutions that will support new and massive amounts of information for providing the best outcome for patients and a manageable process for pharmacists and health professionals.
Physician assistant, nursing, and physician programs have been advancing genomics education during the past few years. Their progress provided potential models for consideration by the pharmacists.
Lessons from physician assistant education
Four professional organizations advocate for genomics education in the interest of the 159 accredited physician assistant programs and 88,000 practicing physician assistants in the United States. The groundwork for integrating genomics into physician assistant education and clinical practice began in 2000 with a conference about genetics in the physician assistant curriculum, followed over the years by a series of forums on the subject. A turning point came in 2006 when the Accreditation Review Commission on Education for the Physician Assistant incorporated genetics into the physician assistant professional standards and American Academy of Physician Assistants was awarded a grant from NCHPEG to develop a new program to educate physician assistants, physician assistant students, and physician assistant educators about the role of genetics within a clinical setting. 15 From 2009 to 2011, the physician assistant profession saw a collaboration with G2C2 on education resources, representation at NCHPEG, a grant to the National Commission on Certification of Physician Assistants Foundation for genetics, a genetics education presentation at NIH by physician assistants to physicians, formation of genomics education working groups, development of focused to-do lists by each of the physician assistant professional groups, and launch of a bimonthly genetics column in the Journal of the American Academy of Physician Assistants.
Lessons from nursing education
The more than 3 million nurses in the United States could benefit from knowing more about the relevancy of genomics to their u r n a l o f t h e A m e r i c a n P h a r m a c i s t s A s s o c i a t i o practice, education, and research. A Genetics/Genomics Nursing Competency Initiative was launched by NHGRI and National Cancer Institute colleagues in an effort to inform, prepare, and implement change in the nursing profession. A 2005 survey showed that nearly 30% of nursing schools had no genetics in the curriculum. When they did, it was usually less than an hour or between 1 and 5 hours. 16 A subsequent survey in 2008 showed that most faculty in Bachelor of Science in Nursing programs rated their knowledge of genetics and genomics as low or very low, 83% agreed or strongly agreed that preparing nurses to use genetic and genomic information was an important role for nurse educators, 93% agreed or strongly agreed that now was the time to start teaching genetics and genomics, 31% had already made curriculum changes, and 66% intended to make changes within 6 months. Barriers were similar to other health professional surveys (e.g., curriculum too full, faculty with insufficient genetic/genomic knowledge). 17 
Through consensus, nurses created the Essentials of Genetics and Genomic Nursing: Competencies and, Curricula
Guidelines (2nd ed.), which is now endorsed by 50 organizations to guide the academic preparation of the nursing workforce to deliver genetic/genomic competent health care.
18 The Competency Outcome Indicators were then developed in response to faculty request for delineation of specific areas of knowledge and nursing practice outcome indicators for each competency. 18 Using the competencies as the framework for mapping resources, a shared competency-driven Web-based repository of genetic/genomic educational tools (i.e., G2C2) was created.
The American Association of Colleges of Nursing Baccalaureate and Masters Accreditation Essentials now include genetics and genomics as important content for the educational preparation of nurses. A Faculty Champion Initiative was launched in 2009 as a model intervention to support faculty from schools of nursing undergoing accreditation in 2010-11 to enable programs to meet these new requirements.
19,20 NH-GRI funded the program to engage 20 nursing faculty for 1 year as champions of genetics. The National Council of State Boards of Nursing recently funded a year-long genetics education program to train nursing administrator-educator teams in genetics and genomics 21 The goal is to build a network of genomic nursing practice educators and leaders, establish a model for bringing innovation to the practicing nursing workforce, and provide consultants to other institutions that are building their genetics and genomics competency.
Lessons from primary care physician education
Reports show that the vast majority of physicians believe that genetics can affect a patient's drug response 22 but that most physicians are lagging in their knowledge of PGx.
Medical school and residency education contains varying amounts of genomics content, but little is known about pharmacogenetic content specifically. Practicing primary care providers have a wide array of competing CME priorities, and for many, genomics and PGx are not viewed as a high priority. NCHPEG, specialty medical societies, and the American Medical Association have developed education resources for physicians; however, like physician assistants, nurses, and pharmacists, physicians are faced with a vast array of competing priorities. On a local health-system level, the Genomic Medicine Institute of El Camino Hospital provides an exemplar with the 10-part monthly workshop and dinner series it offers, titled Medicine's Future: Genomics for Practicing Doctors. u r n a l o f t h e A m e r i c a n P h a r m a c i s t s A s s o c i a t i o small-group discussion: Building PGx competency Small breakout sessions were used to gain interorganizational perspectives on several topics and to brainstorm about potential opportunities and challenge when building PGx competencies. In three small groups of nine people each, participants discussed core genomic education needs for and barriers to building PGx learning for pharmacists in the next 5 years in order to get the discipline progressing on the same learning curve. Questions discussed included the following: (1) What are the core genomic educational needs of all pharmacists in the next 5 years? (2) What are the core genomic educational needs unique to each pharmacist practice setting in the next 5 years? (3) What are the barriers and potential facilitators of pharmacist education in genomics?
identified core genomic educational needs Terminology. A primary need is a shared understanding of terminology and definitions to consolidate thinking and facilitate an exchange of information. A common language creates a baseline for professional discussion, debate, decision making, classification, record keeping, data sharing, and creation of education programs, guidelines, and standards. It helps ensure similar interpretation of genomic tests and research results. A common language empowers patients to research topics and ask informed questions of pharmacists and other health care providers.
Knowledge. Students and pharmacists must have a common core of genomics knowledge. Students should enter pharmacy school with adequate basic science background to build upon. Student pharmacists should gain competency in basic concepts of PGx nomenclature and applications in pharmacy practice. Pharmacists in different types of pharmacy practice will need specialized information and training. Many new pharmacy school graduates will continue on to residency programs where they can refine their PGx knowledge and skills. Others will depend on continuing professional education.
Interpretation. An ability to interpret and understand predictive values, metrics, and clinical utility for PGx test results is needed. Understanding the evidence and being able to assess the outcomes of clinical research studies is important for effectively using PGx in patient care.
Communication. Students and pharmacists must be able to synthesize and communicate PGx information such that it is usable by the health care team and patients.
Professionalism. It is important to recognize that emerging technologies will affect the work of pharmacists and to find ways to incorporate PGx information and skills into professional practice in order to ensure effective communication with patients, colleagues, and other health professionals.
Core genomic educational needs unique to each pharmacist practice setting
The small-group discussions focused on many different sectors of pharmacists (described below) and considered the specific education needs of each.
Community pharmacists will need skills for accessing understandable PGx information on an as-needed basis. They must be able to participate in prescribing decisions based on patients' disease status, physiologic variables affecting drug response and toxicity, treatment guidelines, genetic test results, and drug interaction information. Community pharmacists must have access to information about test reliability and the strength of genetic biomarkers in predicting drug responses. They must have the confidence to combine training, experience, and decision-making algorithms for making informed choices in patient care.
As expert members of patients' health care team, pharmacists in major integrated health systems will need specialized skills and knowledge tailored to their particular populations. Pharmacists often are responsible for designing medication regimens and are instrumental in ensuring that patients are discharged to a dependable pharmacy resource in the community and that their personalized information is carried with them if mobility is a factor. Health-system pharmacists may also need to consider unique environmental exposures and physiological stressors that can complicate decision making, such as in the military health care system.
Pharmacists working in managed care will need to be facile with policy issues, drug utilization reviews, health care technologies (e.g., electronic prescribing), formulary management, and outcomes research. Standards and guidelines will be valuable for this practice setting.
Consultant pharmacists, who often work with older patients taking multiple medications, must have special knowledge about the relationship between polypharmacy and genetic risk factors. Consultant pharmacists may be expected to draw on a broad range of skills, including those previously enumerated for community and health-system pharmacists.
As for pharmacist researchers, their learning in PGx needs to be targeted to trial design, drug development, and data distillation and interpretation. Toolkits would be beneficial to this practice setting.
Barriers and potential facilitators
The identified barriers to building PGx education across the profession include that pharmacists work in different settings nationwide, under different regulations, and without a signature decision-support resource for linking genomics to prescribing (Table 4) . Guidelines for pharmacists to recommend PGx testing and services are inconsistent, as are payment and insurance reimbursements.
Many schools and organizations offer PGx curriculum or continuing education credits, but often not in a coordinated fashion. Many faculty members are unprepared to teach PGx or overburdened with other academic responsibilities. The idea of adopting a preceptor model for teaching PGx was raised.
Some stakeholders may be waiting for more evidence about the impact of PGx before fully endorsing it for pharmacy education. NCHPEG is one organization studying options (and providing tools) for engaging the wide range of stakeholders, r n a l o f t h e A m e r i c a n P h a r m a c i s t s A s s o c i a t i o n www.japha.org 
Pharmacist education in PGx for the next 5 years
Small breakout groups also were used on the second day of the meeting to gain interorganizational perspectives and identify concrete steps for the next 5 years in (1) student pharmacist education, (2) pharmacy resident education, and (3) practicing pharmacist education.
student pharmacist education
Resource development. Students entering pharmacy school should have sufficient knowledge in genetics to be ready for advanced concepts. Faculty will need additional peer-reviewed resources to build and sustain their own knowledge in the field. Areas for student pharmacist learning must be established and mapped to the Accreditation Council for Pharmacy Education (ACPE) science curriculum. A model curriculum and cases for simulation learning should be developed and PGx preceptors identified, as described by ACPE. 24 Champions for PGx education will become leaders and advocates for integration of student and graduate education.
Resource dissemination. Educators should be provided with access and the ability to share credible resources through sites such as PharmGenED and G2C2.
Experiential learning. Pharmacy preceptors and other sources of experiential PGx education should be provided to enhance the ability of students to apply PGx in the care of patients.
Pharmacy resident education
Benchmark residency programs. A survey of pharmacy residents should be conducted to determine the current level of curriculum content in genetics and PGx. The results may help define optimal educational standards and guide the development of learning tools, including electronic resources and cases for simulation learning. Leaders from residency programs that already focus on PGx (e.g., St. Jude Children's Research Hospital, University of California, San Diego/Department of Veterans Affairs, Vanderbilt Hospital) may be keen to help expand current PGx training as a component in general residency programs or be able to provide advice in creating additional specialized residencies focused on PGx. Residency program standards will be revised soon, so this would be ideal for consideration of PGx incorporation.
Review curricula on PGx. Curriculums on PGx should be assessed and shared. Redundancies in effort should be avoided.
Competency development. Develop and harmonize resident PGx education competencies with student pharmacist PGx competencies.
Expand PGx curriculum. Expand residency PGx curriculum if a need is identified.
Practicing pharmacist education
Model Pharmacy Act. Develop an agenda to ensure that legislative efforts (e.g., the Model Pharmacy Act 25 ) incorporate incentives for appropriate use of PGx. Wording related to the delivery of PGx services should be placed in the Model Pharmacy Act.
Resource development. Encourage the creation and use of electronic resources that facilitate the use of PGx in care.
Harmonization. Harmonize terminology and quality measures to be used to assess performance outcomes.
Faculty champions. Develop and support experts/leaders in PGx.
Role delineation. Identify roles/responsibilities of team members (including pharmacists) for implementing PGx services. Education: lack of quality teaching resources including preceptors; few PGx faculty at education institutions; varied competencies, curriculum, and preprofessional requirements; curricula overload (competing priorities, methodology, volume); lack of understanding of relevance of PGx to current practices (perceived as futuristic); lack of collaboration among interdisciplinary team members; lack of demand for services; public genomic literacy Access to resources. Enhance information and alerts that practitioners receive through pharmacy software tools. Genomics updates from software vendors should be coordinated with continuing education learning goals. Access to FDA labeling announcements should be expanded.
Pharmacy organizations are prepared to work together to implement their jointly identified strategies (Table 5) Genomic discoveries relevant to medication selection and management are exponentially advancing. Pharmacist stakeholders present at this meeting perceived the application of PGx in health care as a major emerging opportunity for their profession. Enhanced PGx education for pharmacists from the earliest stages of training through the latter phases of their careers was recognized as priority. Maintaining competency in a time of rapidly evolving knowledge will require a life-long commitment to learning and access to credible resources for educators. The meeting provided concrete action steps required to meet current challenges and to build toward the future needs of pharmacists in the area of PGx.
